Differences between Iboga and LSD: A Comparison of Microdosing Two Hallucinogens

Many users from the psychedelic community report positive effects of so-called microdosing.

In this article, we compare the African plant Iboga with the substance whose use in microdosing is probably the most common and well-known: LSD.

We answer the most important questions about effects, benefits, risks, and safety, examine the current state of research on the topic, and look at the legal situation to gain a comprehensive overview of microdosing with LSD or Iboga.

Enjoy reading the blog post!

Note: All described contents are based on scientific sources or subjective experience reports and are not to be understood as instructions or recommendations for the consumption of Iboga or the use of LSD.

Microdosing involves taking very small amounts of psychedelics to benefit from their effects without experiencing the typical intense "high" of a trip. Both Iboga and LSD can be used to pursue therapeutic goals.

For LSD, about 1/10 of the usual dose for a classic trip is often used – the goal is a more subtle effect that allows one to continue with everyday life.

In the world of microdosing, even less than 1% of the full-dosing amount is often used to leverage self-optimization or "self-therapeutic" effects.

Both LSD and Iboga act on 5-HT2A receptors in the brain, a specific type of serotonin receptor. By affecting these receptor systems, perception, attention, and sensation are influenced in humans, and brain plasticity is increased.

Despite this commonality, LSD and Ibogaine differ in their effects, as both substances bind to many other receptors, which influences their pharmacological profile and the resulting trips. Although the typical trip experiences are absent during microdosing, users report substance-specific differences even at these low doses.

According to user statements, the onset of action for LSD occurs after 30-90 minutes, and for Iboga after 1-3 hours. The two substances also differ in their duration of action, if one believes the reports of microdosing-experienced psychonauts: while LSD consumption shows clear effects for only 6-10 hours, Ibogaine acts for an average of 12-36 hours. For both psychedelics, after-effects after ingestion, the so-called "psychedelic afterglow," are to be expected – and are clearly desired in the context of microdosing.

Lysergic acid diethylamide is considered one of the most famous hallucinogens, inspiring LSD users since the 1960s. With the worldwide ban of the psychedelic, both private LSD consumption and scientific research declined sharply, which is why there is currently insufficient data on the use of different dosages. The existing studies are limited, and the few controlled placebo studies in recent years have not yet provided clear, long-term evidence for the alleged benefits of LSD microdosing outside strictly therapeutic settings. It is clear that LSD consumption unfolds its effect in the brain through interaction with serotonin receptors, which explains the drug's special properties in both high-dosing and microdoses.

LSD microdosing is often associated by users with increased concentration, more creativity, or enhanced performance. Some users report a "clearer perception," less mental tension, and more focus.

With Iboga microdosing, according to user reports, subtle changes occur that are less about a daily performance boost and more about "inner work," emotional balance, and a deeper engagement with oneself.

In contrast to experiences with high doses of Iboga, experience reports suggest that no hallucinations occur when taking microdoses. Users report increased attention and the targeted use of small amounts of Iboga to better cope with personal crises or challenges.

Scientific results suggest that ibogaine, the main active ingredient in the Tabernanthe iboga plant from Central Africa, could play a significant role in treating addiction by alleviating withdrawal symptoms. A possible reduction of cravings in alcohol and drug addiction, as well as the mitigation of symptoms in mental illnesses as support for psychotherapy, are also discussed by pharmacologists as potential therapeutic effects. Pharmacological data indicate that the active ingredient from the Iboga shrub could be supportive in the treatment of mental illnesses such as major depression, pathological anxieties, and post-traumatic stress disorder (PTSD) under certain conditions.

However, since no medication containing Iboga or Ibogaine is currently approved in Germany, medical personnel are not allowed to carry out any treatment or psychotherapy with these substances.

Both substances carry uncertainties – even with microdosing.

For LSD, which is entirely produced in the laboratory, or its legal derivatives, precise dosages are possible through exact active ingredient quantities; however, there is always a risk of incorrect dilutions or other dosing errors. Furthermore, there is a lack of comprehensive long-term data on all effects of microdosing, possible interactions with other substances or medicines, and risks for certain pre-existing conditions.

Iboga is purely plant-based, yet pharmacologically complex. Even in very small doses, ibogaine affects the nervous system and the cardiovascular system and can have varying degrees of influence depending on the individual.

Medical research suggests a great potential for iboga, while some pharmacological research groups warn against unsupervised use, as ibogaine can adversely affect heart rhythm and because dangerous interactions with other substances are possible.

The question of the legal status of psychedelics is one of the most pressing questions that interested parties repeatedly ask themselves.

The good news first: both the Tabernanthe iboga shrub and its most important alkaloid, ibogaine, are not regulated in Germany, meaning that anyone interested can legally acquire iboga for private use, for example, as a tincture, without having to fear legal consequences.
LSD, however, has been banned in Germany for decades, but legal derivatives of the substance repeatedly appear on the market as so-called research chemicals. These research chemicals can be legally acquired for scientific purposes and often serve as a substitute for illegal hallucinogens like LSD for researchers.

While LSD microdosing is mainly discussed in the context of self-optimization and private use, iboga is gaining increasing interest in scientific-medical contexts, for example, from pharmaceutical companies. The active ingredient ibogaine is being investigated for its potential uses in addiction issues (e.g., opiates, alcohol, drugs) and mental illnesses, with current study results indicating high therapeutic potential.

However: Both approaches are not yet fully scientifically validated. Especially with iboga microdosing, research is still young and highly dependent on controlled studies to assess safety and efficacy in the long term.

But for ibogaine, LSD, psilocybin, and other psychedelics, thanks to the "Psychedelic Renaissance" in recent years, there are newer, promising studies whose results, however, are not yet broadly applicable to a large group of patients within a legally secure framework.

• For everyday optimization (concentration, creativity, lower stress levels), LSD microdosing might be more interesting – with the caveat that the scientific basis is still limited and the substance, unlike Iboga, is illegal in Germany.
  
  

• For deeper, self-therapeutic-oriented use, Iboga seems more relevant, especially for people who want to address drug withdrawal or spiritual-psychological growth. The problem here: Iboga or ibogaine are not approved as medicines in Germany and cannot be used by doctors and therapists in treatments or as part of psychotherapy.
  
  

• Medical safety aspects of LSD & Iboga: Due to the effects of both psychedelic substances on the cardiovascular system, a medical examination should take place before use for safety reasons.
  
  

• Important for both substances: Even with microdosing, mindfulness, informed action, respect for the substance, and thorough self-observation are central prerequisites for safe experiences.

• Murphy R. J., Muthukumaraswamy S., de Wit H. (2024). Microdosing Psychedelics: Current Evidence From Controlled Studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May;9(5): 500-511. doi: 10.1016/j.bpsc.2024.01.002.

• Fernandes-Nascimento M. H., Viana-Ferreira K., Chaves B. D. R., Negrão A. B., Wang Y. P. (2022). Ibogaine microdosing in a patient with bipolar depression: a case report. Braz J Psychiatry. 2022 Jul 27;44(4): 462–3. doi: 10.47626/1516-4446-2021-2359.

• Evens R., Schmidt M. E., Majić T., Schmidt T. T. (2023). The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics. Ther Adv Psychopharmacol. 2023 May 29; 13:20451253231172254. doi: 10.1177/20451253231172254.

• Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. (2021) Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci Rep 11, 1941 (2021). https://doi.org/10.1038/s41598-021-81446-7.

• Seragnoli F., Pires Martins D., Thorens G. (2021). Microdosage de LSD : pratiques et risques. Rev Med Suisse. 2021 Jun 9; 17(742):1 108-1110.

• Yoo M., Sakopoulos S. (2025). Birth of the Psychedelic Industry: Capitalising on the Psychedelic Renaissance. In: Future Humanities Vol. 3, issue 1 (May 2025). https://doi.org/10.1002/fhu2.70004